Medtronic won European CE Mark approval to introduce its Valiant Navion thoracic stent graft for treating lesions within the descending thoracic aorta such as thoracic aortic aneurysms (TAA), blunt traumatic aortic injuries (BTAI), and penetrating atherosclerotic ulcers (PAU). The system received FDA approval in October of this year. The Valia (Read more...)
PerQseal Absorbable, Sutureless Large-Bore Closure Device Coming to Europe
Vivasure Medical, a Galway, Ireland company, is launching in Europe its PerQseal closure device for use in large vessel femoral arteriotomies following large-bore transcatheter procedures, such as aortic valve replacements. Though minimally invasive transcatheter procedures have revolutionized cardiovascular care, closing the access sites (Read more...)
Point-of-Care BRCA1 Mutation Testing in 20 Minutes
BReast CAncer gene one (BRCA1) is one of the best-known genes linked to breast cancer risk. Unfortunately, the technology to spot the gene requires a lab and expertise at interpretation. Researchers at Louisiana State University have now developed a smartphone-based system called FLuoroZen that can test for the cancer-related BRCA1 mutation at the (Read more...)
Uncategorized
Zimura-Lucentis combination safe in wet AMD patients in phase 2a trial
Zimura, a complement factor C5 inhibitor, was found to be well tolerated in combination with Lucentis in a phase 2a clinical trial, Ophthotech announced in a press release.Sixty-four patients with wet age-related macular degeneration were enrolled in t…
Uncategorized
Quarterly loss decreases for ProQR
ProQR Therapeutics reported a net loss of 6 million euros, or 0.18 euros per share, in the third quarter of 2018 compared with a net loss of 10.5 million euros, or 0.42 euros per share, in the previous year’s third quarter.Research and development cost…
Uncategorized
Santen launches Verkazia in Europe to treat VKC in children
Santen U.K. Ltd. announced the launch of Verkazia eye drops in Europe for the treatment of severe vernal keratoconjunctivitis in adolescents and children at least 4 years old.Verkazia (0.1% cyclosporine), an immunomodulator that targets the underlying …